<DOC>
	<DOCNO>NCT01272570</DOCNO>
	<brief_summary>The 3 Specific Aims ( 1 ) To determine prevalence , incidence severity oral condition postmenopausal early stage breast cancer survivor within first 18 month adjuvant Aromatase Inhibitor ( AI ) therapy , ( 2 ) To determine oral health quality life among postmenopausal early stage breast cancer survivor receive AI therapy , ( 3 ) To determine utilization dental care among postmenopausal woman receive AIs history early stage BCa time . The hypothesis pilot study AIs negatively impact oral health oral health quality life set breast cancer survivor . Further , hypothesize dental visit underutilized woman BCa undergo adjuvant AI therapy .</brief_summary>
	<brief_title>Oral Health Oral Health-Related Quality Life Early Stage Breast Cancer Survivors</brief_title>
	<detailed_description>This 2 arm prospective study . PM woman receive breast care , without breast cancer , University Michigan eligible . The study procedure include : survey/questionnaires , oral exam perform Michigan Center Oral Health Research ( MCOHR ) specimen collection , medical chart review . The goal study collect dental data oral health quality life data woman receive AI therapy . This study administer treatment drug participant .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Postmenopausal define NCCN ( follow ) Prior bilateral oophorectomy Age equal great 60 year age Age le 60 amenorrheic 12 month absence chemotherapy , tamoxifen , toremifene ovarian suppression FSH estradiol postmenopausal range If take tamoxifen toremifene age less 60y , FSH plasma estradiol level postmenopausal ranges71 . Individuals capable consent self administer survey instrument . At least 15 teeth present . AI user : Diagnosis BCa Histologic confirm diagnosis BCa : Stage 0 , I , II , III evidence metastatic disease . Treatment AI clinically indicate ( AI may anastrozole , exemestane letrozole ) . Subjects may prior tamoxifen raloxifene . Subjects may chemotherapy and/or radiation therapy . Must within first year consecutive AI therapy . If subject start AI , discontinue , restart , accept study long past therapy exceed 12 month current therapy exceed 12 month . Controls : No Diagnosis cancer . Patients must diagnosis cancer ( Not include history thyroid skin cancer ) . Metastatic BCa ( AI treat group : fully resect locally recurrent disease permit patient render without evidence disease ) . Significant psychiatric illness/social situation would preclude completion questionnaire Chronic medication know affect periodontal status ( calcium antagonist , anticonvulsives , immunosuppressive ( &gt; prednisone 7.5mg daily ) . NSAIDS bisphosphonates permit . Premedication Conditions require antibiotic therapy evaluate casebycase basis . ( Patients take prophylaxis joint replacement exclude . )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>breast</keyword>
	<keyword>oral</keyword>
	<keyword>cancer</keyword>
</DOC>